Drug Shortage
Pfizer Warns of ‘Near-Term Stock Out’ of Penicillin Used for Treating Syphilis in Pregnant Women After Recall
Pfizer; penicillin recall; Bicillin L-A; syphilis treatment; pregnant women; drug shortage; congenital syphilis; FDA; Extencilline; public health
Compounders just lost their case to put obesity drug tirzepatide back in shortage
Tirzepatide, compounding, FDA, drug shortage, Eli Lilly, Zepbound, Mounjaro, legal case, Outsourcing Facilities Association (OFA), GLP-1 medications
Compounders Sue FDA Over Removal of Semaglutide from Drug Shortage List
Semaglutide, FDA, drug shortage, compounders, lawsuit, Ozempic, Wegovy, Outsourcing Facilities Association
FDA Reaffirms End of Tirzepatide Shortage, Impacting Compounders
FDA, tirzepatide, GLP-1, drug shortage, compounders, Eli Lilly, Mounjaro, Zepbound
FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists
FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability
FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy
FDA, Novo Nordisk, Ozempic, Wegovy, drug shortage, semaglutide, obesity treatment, type 2 diabetes treatment
FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Compounding
Tirzepatide, FDA, drug shortage, compounding pharmacies, GLP-1 medications
FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Access to Compounded Versions
FDA, tirzepatide, drug shortage, compounded medications, Eli Lilly, type 2 diabetes, weight loss, GLP-1 medications
Compounding Pharmacies Challenge FDA’s Decision to End Eli Lilly’s GLP-1 Drug Shortage
Eli Lilly, GLP-1 drug, FDA, compounding pharmacies, drug shortage, lawsuit
Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing
Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.